Novartis AG (ADR)  

(Public, NYSE:NVS)   Watch this stock  
Find more results for NVS
+0.69 (0.73%)
Dec 22 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 95.03 - 95.54
52 week 77.90 - 96.97
Open 95.27
Vol / Avg. 1.24M/1.21M
Mkt cap 257.08B
P/E 22.96
Div/yield 2.76/2.90
EPS 4.15
Shares 2.45B
Beta 0.55
Inst. own 10%
Feb 27, 2015
Novartis AG Annual Shareholders Meeting - 4:00AM EST - Add to calendar
Jan 27, 2015
Q4 2014 Novartis AG Earnings Release - 3:00AM EST - Add to calendar
Dec 4, 2014
Novartis AG at Societe General Premium Review Conference
Dec 2, 2014
Novartis AG at Berenberg European Conference
Dec 2, 2014
Novartis AG at Bernstein BioSimilars Conference
Nov 19, 2014
Novartis AG at Jefferies Healthcare Conference
Nov 12, 2014
Novartis AG at UBS European Conference
Nov 11, 2014
Novartis AG at Credit Suisse Healthcare Conference
Nov 6, 2014
Novartis AG at Bryan Garnier Healthcare Conference
Oct 28, 2014
Q3 2014 Novartis AG Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 23.32% 15.79%
Operating margin 20.59% 18.52%
EBITD margin - 27.97%
Return on average assets 9.91% 7.42%
Return on average equity 17.46% 12.79%
Employees 135,000 -
CDP Score - 96 B


Lichtstrasse 35
BASEL, 4056
+41-61-6969511 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. It has five segments: Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines and diagnostics, which include human vaccines and blood-testing diagnostics, and consumer health, which include over-the-counter medicines (OTC) and Animal Health. In February 2014, it acquired CoStim Pharmaceuticals, Inc.

Officers and directors

Joerg Reinhardt Ph.D. Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Joseph S. Jimenez Chief Executive Officer, Member of the Executive Committee
Age: 54
Bio & Compensation  - Reuters
Ulrich Lehner Vice Chairman of the Board of Directors, Non-Executive Director
Age: 68
Bio & Compensation  - Reuters
Harry Kirsch Member of the Management Board, Chief Financial Officer
Bio & Compensation  - Reuters
Peter Kornicker Chief Compliance Officer
Bio & Compensation  - Reuters
Felix R. Ehrat Ph.D. Group General Counsel, Member of the Executive Committee
Age: 57
Bio & Compensation  - Reuters
Juergen Brokatzky-Geiger Ph.D. Head Human Resources and Member of the Executive Committee
Age: 62
Bio & Compensation  - Reuters
Michele Galen Head Communications
Bio & Compensation  - Reuters
Paul van Arkel Head of Corporate Strategy and External Affairs
Bio & Compensation  - Reuters
Erwin Vanhaecke Ph.D. Head Novartis Group Quality
Bio & Compensation  - Reuters